Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Takara Bio Acquires Oncology Business from M's Science
November 1, 2010
- Daiichi Sankyo: Anti-Flu Drug Inavir
November 1, 2010
- The Pharma Gospel of Praise
November 1, 2010
- Nobelpharma Considers Independent Marketing of New Products
November 1, 2010
- Nichi-Iko Ties Up with Aprogen of South Korea for Biosimilars
November 1, 2010
- Fixed-Dose ARB/CCB Combinations Reduce ADRs: Prof. Hasebe
November 1, 2010
- Pfizer Acquires 40% Stake in Brazilian Generic Company
November 1, 2010
- Generics' Share in Japan Will Not Become as Large as in the West: Prof. Nakamura
November 1, 2010
- COPD Treatments, Smoking Cessation Aids to Show Double-Digit Growth: Fuji-Keizai
November 1, 2010
- Mediscience: FY2010 Business Results Fall Short of Forecasts
November 1, 2010
- IMSUT Objects to Asahi Shimbun News
November 1, 2010
- JMA, JAMS Oppose JSLN's Cholesterol GL for Longevity
November 1, 2010
- BI Inaugurates New Inhaler Factory
November 1, 2010
- Japan Can Contribute to Global Development by Earlier Participation: Dr Yoshikawa of Eli Lilly Japan
November 1, 2010
- 5-Fold Increase in Pollen Counts Expected in Spring 2011
November 1, 2010
- Japan's First IP Fund Starts Operation
November 1, 2010
- Diagnostic Imaging Is Japan's Advantage: Ms Sawada of Shionogi
November 1, 2010
- Catalent Embarks on Master Cell Bank Development Business in Japan
November 1, 2010
- Vidaza Recommended for Approval
November 1, 2010
- “Medical Innovation Center Scheme”Proposed by Dr Kayama
November 1, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…